Organon, Shanghai Henlius Biotech: Phase 3 study of HLX14 met primary endpoints

Shanghai Henlius Biotech and Organon announced that the phase 3 comparative clinical trial for the investigational Prolia and Xgeva biosimilar HLX14 met the primary endpoints. In 2022, Henlius entered into a license and supply agreement with Organon for the exclusive commercialization rights to two biosimilar candidates, including HLX14. The agreement covers markets such as the United States, the European Union, and Canada. An exception to the agreement is China.